InvestorsHub Logo
Followers 28
Posts 2529
Boards Moderated 0
Alias Born 05/08/2015

Re: 3X Charm post# 193328

Thursday, 11/11/2021 4:29:05 PM

Thursday, November 11, 2021 4:29:05 PM

Post# of 233148
What is $7.6m compared to the bozo, "fat Tony", who wasted 27 million shares by hiring Pestell??

"The ProstaGene acquisition was essentially about a prostate cancer diagnostic. The concept of the acquisition was masterminded by Executive Anthony Caracciolo who at the time was CytoDyn’s Executive Chairman of the Board when the deal was initially announced in July 2018. Nader Pourhassan was the CEO, but at the time had no decision-making power with respect to the acquisition. Many investors may not realize, but the executive chairman is higher in rank than CEO and Caracciolo stepped into that role in January 2017. Many thought that his Gilead resume would be instrumental in inking a deal. On closing of the acquisition in November 2018 Dr. Pestell was not only welcomed as the newest board member, but was also the company’s Interim Chief Medical Officer. This was all Caracciolo’s doing until a more balanced board led by Dr. Scott Kelly came to fruition in January 2019. The fact is Caracciolo didn’t resign until January 10, 2019 when David Welch joined the board. So issues that predate January 10, 2019 are on Caracciolo’s watch, not Pourhassan’s. An interesting anecdote is that Caracciolo also presided over the failed receptor occupancy test done by IncellDX."

NADER FIRED PESTELL WITHOUT CAUSE, COSTING SHAREHOLDERS $7.6M.


My comments are just my opinions and should NOT be taken as investment advice.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News